NEA Management Company’s Phathom Pharmaceuticals PHAT Stock Holding History

NEA Management Company’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.3M	Hold	1,960,169	–	–	1.34%	12
2026 Q1	$21.8M	Hold	1,960,169	–	–	1.24%	13
2025 Q4	$32.5M	Hold	1,960,169	–	–	1.66%	14
2025 Q3	$23.1M	Hold	1,960,169	–	–	1.27%	16
2025 Q2	$18.8M	Hold	1,960,169	–	–	1.42%	16
2025 Q1	$12.3M	Hold	1,960,169	–	–	0.95%	20
2024 Q4	$15.9M	Hold	1,960,169	–	–	0.9%	19
2024 Q3	$35.4M	Hold	1,960,169	–	–	1.93%	14
2024 Q2	$20.2M	Hold	1,960,169	–	–	1.52%	17
2024 Q1	$20.8M	Hold	1,960,169	–	–	1.29%	18
2023 Q4	$17.9M	Buy	1,960,169 +683,574	+54%	+$5.89M	1.19%	17
2023 Q3	$12.2M	Hold	1,276,595	–	–	0.95%	25
2023 Q2	$18.3M	Buy	+1,276,595	New	+$14.7M	1.4%	21

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

NEA Management Company's PHAT Position: Q2 2026 in Review

NEA Management Company held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 1,960,169 shares worth $21.3M. The position accounts for 1.34% of the portfolio, ranked #12.

NEA Management Company first reported a position in PHAT in Q2 2023 and has held it in 13 quarters since. The position peaked at $35.4M in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

NEA Management Company held 1,960,169 shares of Phathom Pharmaceuticals worth $21.3M as of Q2 2026.
NEA Management Company left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
Phathom Pharmaceuticals made up 1.34% of NEA Management Company's portfolio in Q2 2026, its #12 holding.
NEA Management Company first reported a position in Phathom Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
NEA Management Company's Phathom Pharmaceuticals position peaked at $35.4M in Q3 2024.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.